{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:36:34Z","timestamp":1772714194092,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T00:00:00Z","timestamp":1313625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T00:00:00Z","timestamp":1313625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/gt.2011.111","type":"journal-article","created":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T10:29:19Z","timestamp":1313663359000},"page":"404-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Sustained correction of OTC deficiency in spfash mice using optimized self-complementary AAV2\/8 vectors"],"prefix":"10.1038","volume":"19","author":[{"given":"L","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Morizono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"McMenamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M L","family":"Batshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,18]]},"reference":[{"key":"BFgt2011111_CR1","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1067\/mpd.2001.111836","volume":"138","author":"ML Batshaw","year":"2001","unstructured":"Batshaw ML, MacArthur RB, Tuchman M . Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138: S46\u2013S54; discussion S54\u201345.","journal-title":"J Pediatr"},{"key":"BFgt2011111_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1203\/PDR.0b013e3181a27a16","volume":"66","author":"L Krivitzky","year":"2009","unstructured":"Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML . Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009; 66: 96\u2013101.","journal-title":"Pediatr Res"},{"issue":"Suppl 1","key":"BFgt2011111_CR3","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/j.ymgme.2003.08.027","volume":"81","author":"JV Leonard","year":"2004","unstructured":"Leonard JV, McKiernan PJ . The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004; 81 (Suppl 1): S74\u2013S78.","journal-title":"Mol Genet Metab"},{"key":"BFgt2011111_CR4","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.271.7.3639","volume":"271","author":"X Ye","year":"1996","unstructured":"Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM . Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996; 271: 3639\u20133646.","journal-title":"J Biol Chem"},{"key":"BFgt2011111_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1203\/00006450-199704000-00012","volume":"41","author":"X Ye","year":"1997","unstructured":"Ye X, Robinson MB, Pabin C, Quinn T, Jawad A, Wilson JM et al. Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr Res 1997; 41: 527\u2013534.","journal-title":"Pediatr Res"},{"issue":"Suppl 1","key":"BFgt2011111_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1023\/A:1005369926784","volume":"21","author":"SE Raper","year":"1998","unstructured":"Raper SE, Wilson JM, Yudkoff M, Robinson MB, Ye X, Batshaw ML . Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998; 21 (Suppl 1): 119\u2013137.","journal-title":"J Inherit Metab Dis"},{"key":"BFgt2011111_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/1074-7613(94)90074-4","volume":"1","author":"Y Yang","year":"1994","unstructured":"Yang Y, Ertl HC, Wilson JM . MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433\u2013442.","journal-title":"Immunity"},{"key":"BFgt2011111_CR8","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1073\/pnas.91.10.4407","volume":"91","author":"Y Yang","year":"1994","unstructured":"Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM . Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407\u20134411.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt2011111_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148\u2013158.","journal-title":"Mol Genet Metab"},{"key":"BFgt2011111_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/gt.2008.64","volume":"15","author":"IE Alexander","year":"2008","unstructured":"Alexander IE, Cunningham SC, Logan GJ, Christodoulou J . Potential of AAV vectors in the treatment of metabolic disease. Gene Therapy 2008; 15: 831\u2013839.","journal-title":"Gene Therapy"},{"key":"BFgt2011111_CR11","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854\u201311859.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFgt2011111_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","volume":"16","author":"DM McCarty","year":"2008","unstructured":"McCarty DM . Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16: 1648\u20131656.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymthe.2006.03.009","volume":"14","author":"D Moscioni","year":"2006","unstructured":"Moscioni D, Morizono H, McCarter RJ, Stern A, Cabrera-Luque J, Hoang A et al. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 2006; 14: 25\u201333.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/mt.2009.88","volume":"17","author":"SC Cunningham","year":"2009","unstructured":"Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE . AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther 2009; 17: 1340\u20131346.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1089\/10430349950016942","volume":"10","author":"JE Loeb","year":"1999","unstructured":"Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ . Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295\u20132305.","journal-title":"Hum Gene Ther"},{"key":"BFgt2011111_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ymthe.2004.05.036","volume":"10","author":"A Mian","year":"2004","unstructured":"Mian A, McCormack Jr WM, Mane V, Kleppe S, Ng P, Finegold M et al. Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol Ther 2004; 10: 492\u2013499.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/sj.gt.3301221","volume":"7","author":"JC Paterna","year":"2000","unstructured":"Paterna JC, Moccetti T, Mura A, Feldon J, Bueler H . Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Therapy 2000; 7: 1304\u20131311.","journal-title":"Gene Therapy"},{"key":"BFgt2011111_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.gt.3302417","volume":"12","author":"SM Kingsman","year":"2005","unstructured":"Kingsman SM, Mitrophanous K, Olsen JC . Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Therapy 2005; 12: 3\u20134.","journal-title":"Gene Therapy"},{"key":"BFgt2011111_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/mt.2009.246","volume":"18","author":"L Wang","year":"2010","unstructured":"Wang L, Wang H, Bell P, McCarter RJ, He J, Calcedo R et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther 2010; 18: 118\u2013125.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR20","unstructured":"Bell P, Gao G, Haskins ME, Wang L, Sleeper MM, Wang H et al. Evaluation of AAV Vectors for Liver-directed Gene Transfer in Dogs. Hum Gene Ther (in press)."},{"key":"BFgt2011111_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/mt.2009.245","volume":"18","author":"L Wang","year":"2010","unstructured":"Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther 2010; 18: 126\u2013134.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR22","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653\u20132661.","journal-title":"Blood"},{"key":"BFgt2011111_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.mt.6300355","volume":"16","author":"Z Wu","year":"2008","unstructured":"Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280\u2013289.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/sj.gt.3302133","volume":"10","author":"Z Wang","year":"2003","unstructured":"Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X . Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Therapy 2003; 10: 2105\u20132111.","journal-title":"Gene Therapy"},{"key":"BFgt2011111_CR25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","volume":"109","author":"AC Nathwani","year":"2007","unstructured":"Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109: 1414\u20131421.","journal-title":"Blood"},{"issue":"Part 2","key":"BFgt2011111_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/bj3220625","volume":"322","author":"H Morizono","year":"1997","unstructured":"Morizono H, Tuchman M, Rajagopal BS, McCann MT, Listrom CD, Yuan X et al. Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces \u2018late onset\u2019 hyperammonaemia. Biochem J 1997; 322 (Part 2): 625\u2013631.","journal-title":"Biochem J"},{"key":"BFgt2011111_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.mt.6300049","volume":"15","author":"D Sondhi","year":"2007","unstructured":"Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007; 15: 481\u2013491.","journal-title":"Mol Ther"},{"key":"BFgt2011111_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ymthe.2006.03.008","volume":"14","author":"P Bell","year":"2006","unstructured":"Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, Hoang A et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 2006; 14: 34\u201344.","journal-title":"Mol Ther"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt2011111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2011111","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2011111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:38:07Z","timestamp":1648546687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt2011111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,18]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFgt2011111"],"URL":"https:\/\/doi.org\/10.1038\/gt.2011.111","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,18]]},"assertion":[{"value":"28 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMW is a consultant to ReGenX Holdings, and is a founder of, holds equity in and receives a grant from affiliates of ReGenX Holdings; in addition, he is an inventor on patents licensed to various biopharmaceutical companies, including affiliates of ReGenX Holdings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}